MARKET WIREYahoo! Finance Canada • 22h ago
McKesson Corporation (MCK) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering McKesson Corporation (MCK) market action, institutional positioning, and fundamental catalysts.
Why MCK Stock advanced +0.38% Today — RQD Quant Desk Flash
$998.38 +0.38% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1,001.46
McKesson Corporation (MCK) earns a Roarable Rating of A- (Buy) with 85/100 RQD Confidence. High-quality cash engine (3.6% gross margin, 39% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE A- • STRONG BUY
Cap $115.96B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on MCK Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is MCK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, McKesson Corporation (NYSE: MCK) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 85/100 at a spot price of $998.38 (+0.38% 1D, market cap $115.96B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, MCK ranks #4 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does MCK compare to COR and CAH in the Health Care sector?
▼
Within the Health Care sector (Other Pharmaceuticals), MCK carries a Roarable A- (85/100 RQD), trailing P/E of 24.0x, gross margin of 3.6%, and ROIC of 38.6%. By comparison, COR (Cencora Inc.) holds a B grade (72/100 RQD, P/E 40.6x, ROIC 26.8%, cap $63.13B) and CAH (Cardinal Health Inc.) posts a B grade (73/100 RQD, P/E 37.2x, ROIC 29.7%, cap $58.00B). Among the 5-stock peer group, HLF leads on earnings multiple (5.9x) while MCK leads on capital efficiency (38.6% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for MCK?
▼
Per MCK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0000927653), McKesson Corporation generated $403.43B in revenue (+12.4% YoY), $4.76B in net income, and $5.72B in free cash flow against $84.19B in total assets and $19.70B in total debt. Key quantitative strengths: Strong cash generator (3.6% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1,001.47 (+0.31%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 1.4% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 85/100 (A-) historically ranked in the Top 6% of excess returns over the next 90 days (+9.0% avg 90D alpha vs SPY • 72.9% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSTRONG BUY • A-
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw A · Rk A-
Each axis scored 0–20
12M PRICE TARGET CONE+12.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MCK)Realized 20D OHLCV Swing Band: ±4.5%
Deterministic 5-Pillar Attribution (85/100 Composite)
🔍 WHY MCK SCORES 85/100 (A-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (21% of score)
20D Institutional Volume Accumulation (±4.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (21% of score)
Altman Z-Score 6.96 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▼ #1 Drag / Risk Factor: Macro Regime Fit15/20 pts (-5 pt drag)
Macro rate sensitivity & RSI-14 (59.6) create a -5 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B+$976.57+4% Next Q
77
Q2 (-2Q)Grade A-$1,015.50-5.4% Next Q
80
Q3 (-1Q)Grade A$960.56+3.9% Next Q
82
CurrentGrade A-$998.38+9% Hist 90D α
85
Trajectory: B+ (77) → A- (85)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the MCK Bull Thesis Could Fail
Even with a 85/100 (A-) score, MCK faces multiple-compression risk if 24.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 15.0% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($928.56) or 200D SMA ($864.88) invalidates the momentum regime and cuts Target Base ($1,119.68) toward Bear Floor ($818.67).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $MCK• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MCK Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MCK Stock advanced +0.38% Today — RQD Quant Desk Flash
McKesson Corporation (MCK) advanced +0.38% to $998.38, trading at 90% of its 52-week range ($723.68 – $1030.27). High-quality cash engine (3.6% gross margin, 39% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 90% of its 52-week range ($723.68 – $1030.27) with RSI-14 at 59.6 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±4.5% around $998.38 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable A- (Buy) backed by 3.6% gross margin and $5.7B annual free cash flow.
Live MCK Headlines & Catalysts
MARKET WIRETrefis • 1d ago
Would You Have Held McKesson Stock All The Way Up?Trefis report covering McKesson Corporation (MCK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Is Most-Watched Stock McKesson Corporation (MCK) Worth Betting on Now?Yahoo Finance report covering McKesson Corporation (MCK) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETrefis • 1d ago
Is Buying McKesson Stock Near Its High A Bad Idea?Trefis report covering McKesson Corporation (MCK) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
McKesson (MCK) Stock Dips While Market Gains: Key FactsYahoo Finance report covering McKesson Corporation (MCK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
McKesson Corporation (MCK.F) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering McKesson Corporation (MCK) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Is McKesson (MCK) a Solid Growth Stock? 3 Reasons to Think "Yes"Yahoo Finance report covering McKesson Corporation (MCK) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo Finance • 1d ago
McKesson (MCK) Ascends While Market Falls: Some Facts to NoteYahoo Finance report covering McKesson Corporation (MCK) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 3d ago
Cintas Corporation (CTAS) Gains 15% as Record Q4 Margins Fuel Guidance IncreaseBristol Gate Capital Partners, an investment management company, published its Q3 2026 investor letter for the “US Equity Strategy”. The letter can be downloaded here. The US Equity Strategy lagged the S&P 500 (+2.3%) in
MARKET WIREYahoo • 4d ago
Stay Ahead of the Game With McKesson (MCK) Q2 Earnings: Wall Street's Insights on Key MetricsBesides Wall Street's top-and-bottom-line estimates for McKesson (MCK), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (MCK Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MCK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +23.58%▲ ASCENDING CHANNEL
2026-11-03O $980.9H $998.4L $980.9C $998.4VOL 763.2K
RES: $1,055.2SUP: $856.7SMA50: $928.6SMA200: $864.9
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MCK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
17.8%/yr Implied 5Y Growth
vs. +12.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on MCK today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MCK. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MCK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MCK)
Health Care Rank #4 of 1015
⚔️ COR vs MCK Full Matrix →
1. Head-to-Head Health Care Peer Comparison (MCK vs. COR, CAH, HLF, NUS)
Industry: Other Pharmaceuticals (10 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, McKesson Corporation (MCK) ranks #4 by composite RQD confidence (85/100, grade A-) and #19 by equity capitalization ($115.96B). Within this direct 5-issuer industry benchmark cohort, HLF leads on earnings valuation at 5.9x trailing P/E, while MCK leads on capital efficiency and profitability with 38.6% ROIC and 3.6% gross margin. MCK currently leads its immediate peer cohort in composite quantitative strength at 85/100 (A-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MCK
ACTIVE
McKesson Corporation | A- | 85/100 | 24.0x | 3.6% | 38.6% | +0.38% | $115.96B | Benchmark Subject |
| COR Cencora Inc. | B | 72/100 | 40.6x | 3.6% | 26.8% | +2.12% | $63.13B | /cor-vs-mck → |
| CAH Cardinal Health Inc. | B | 73/100 | 37.2x | 3.7% | 29.7% | +1.54% | $58.00B | /cah-vs-mck → |
| HLF Herbalife Ltd. | C | 64/100 | 5.9x | 77.9% | 34.4% | +1.76% | $1.37B | /hlf-vs-mck → |
| NUS Nu Skin Enterprises Inc. | D | 50/100 | — | 69.4% | 6.7% | +2.80% | $226.3M | /nus-vs-mck → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0000927653 ↗In its most recent audited fiscal period (FY2025, filed 2026-03-31), McKesson Corporation (MCK) reported GAAP revenue of $403.43B (+12.4% vs. FY2024 revenue of $359.05B , and +30.6% cumulative change since FY2023) , GAAP net income of $4.76B, operating cash flow of $6.16B, and free cash flow of $5.72B (+3.1% YoY). On the balance sheet, MCK closed FY2025 with $84.19B in total assets against $19.70B in total debt (Altman Z-Score: 6.96, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-03-31 | $403.43B | $4.76B | $6.16B | $5.72B | $84.19B | $19.70B |
| FY2024 (FY) | 2025-03-31 | $359.05B | $3.29B | $6.08B | $5.55B | $71.08B | $16.63B |
| FY2023 (FY) | 2024-03-31 | $308.95B | $3.00B | $4.31B | -$9.59B | $370.74B | $86.75B |
3. MCK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MCK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, McKesson Corporation (NYSE: MCK) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 85/100 at a spot price of $998.38 (+0.38% 1D, market cap $115.96B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, MCK ranks #4 in composite RQD confidence.
How does MCK compare to COR and CAH in the Health Care sector?
Within the Health Care sector (Other Pharmaceuticals), MCK carries a Roarable A- (85/100 RQD), trailing P/E of 24.0x, gross margin of 3.6%, and ROIC of 38.6%. By comparison, COR (Cencora Inc.) holds a B grade (72/100 RQD, P/E 40.6x, ROIC 26.8%, cap $63.13B) and CAH (Cardinal Health Inc.) posts a B grade (73/100 RQD, P/E 37.2x, ROIC 29.7%, cap $58.00B). Among the 5-stock peer group, HLF leads on earnings multiple (5.9x) while MCK leads on capital efficiency (38.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MCK?
Per MCK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0000927653), McKesson Corporation generated $403.43B in revenue (+12.4% YoY), $4.76B in net income, and $5.72B in free cash flow against $84.19B in total assets and $19.70B in total debt. Key quantitative strengths: Strong cash generator (3.6% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MCK trading relative to its 50-day, 200-day, and 52-week technical levels?
MCK last traded at $998.38 (+0.38% on volume of 720,278 shares), positioning the stock +7.52% above its 50-day simple moving average ($928.56) and +15.44% above its 200-day simple moving average ($864.88). Across its 52-week range of $723.68 to $1,030.27, MCK sits at the 89.6% percentile with a 14-day RSI of 59.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.5% ($953.45 to $1,043.31).
ROARABLE RATING BRIEF • RQD 85/100 (A-)
✓ SEC XBRL & RQD VERIFIED
MCK — McKesson Corporation: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-03-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
McKesson Corporation (MCK) earns a live Roarable RQD composite score of 85/100, corresponding to a A- letter grade (Roarable Buy) at a spot price of $998.38 (+0.38% 1D, market capitalization $115.96B).
- Fundamental Cash Engine (17/20): Anchored by return on invested capital (ROIC) of 38.6%, gross margin of 3.6%, operating margin of 1.5%, and free cash flow yield of 5.00%.
- Whale 13F & Options Flow (18/20) + Insider Conviction (17/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (15/20) + Forensic Balance Sheet (18/20): Incorporates a 0.95x equity beta, Altman Z-Score of 6.96, Piotroski F-Score of 7/9, and Debt/Equity of 0.85x.
2. Business Model, Unit Margins & SEC Financial Trajectory
McKesson Corporation is a NYSE-listed issuer classified under the Health Care sector and the Other Pharmaceuticals industry. Beyond the sector and industry classification, the specific products, customers, and revenue model are not described in the source data.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-03-31), McKesson Corporation (MCK) reported $403.43B in annual revenue (up from $359.05B in FY2024, +12.4% YoY) and $4.76B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($308.95B revenue, $3.00B net income) through FY2025, MCK scaled operating cash flow to $6.16B and free cash flow to $5.72B, backed by $84.19B in total assets against $19.70B in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (A- • RQD 85/100): Strong cash generator (3.6% gross margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 17/20 and Institutional Whale Flow at 18/20, sustained execution supports upside toward the upper end of the $723.68 – $1,030.27 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 24.0x trailing P/E and 19.5x EV/EBITDA against 1.5% operating margins and a 0.95x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
For an investor, the absence of mapped links means this analysis cannot identify ripple effects from the data provided; the sector and industry labels are the only structural context.
- Key Question #1: Can MCK sustain or expand its 1.5% operating margin and 38.6% ROIC against Other Pharmaceuticals peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $403.43B and free cash flow of $5.72B, how will capital allocation balance growth reinvestment against $19.70B in total debt?
- Key Question #3: How sensitive is MCK's 20.2x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.95x)?
MCK Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for McKesson Corporation (MCK) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 22h ago
McKesson Corporation (MCK) Stock Price, News, Quote & History Yahoo! Finance Canada report covering McKesson Corporation (MCK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Trefis • 1d ago
Would You Have Held McKesson Stock All The Way Up? Trefis report covering McKesson Corporation (MCK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Is Most-Watched Stock McKesson Corporation (MCK) Worth Betting on Now? Yahoo Finance report covering McKesson Corporation (MCK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Trefis • 1d ago
Is Buying McKesson Stock Near Its High A Bad Idea? Trefis report covering McKesson Corporation (MCK) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
McKesson (MCK) Stock Dips While Market Gains: Key Facts Yahoo Finance report covering McKesson Corporation (MCK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
McKesson Corporation (MCK.F) Stock Price, News, Quote & History Yahoo! Finance Canada report covering McKesson Corporation (MCK) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Is McKesson (MCK) a Solid Growth Stock? 3 Reasons to Think "Yes" Yahoo Finance report covering McKesson Corporation (MCK) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Yahoo Finance • 1d ago
McKesson (MCK) Ascends While Market Falls: Some Facts to Note Yahoo Finance report covering McKesson Corporation (MCK) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
MCK Bull vs. Bear Conversation Board — What's Your Call at $998.38?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MCK 🐻 33% BEARISH CONVICTION
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH
🎯 Target: $1,163.66 (+17.0%)
📌 Pinned Debate Per the RQD rating, a 38.6% ROIC combined with Altman Z 6.96 and Piotroski F 7/9 points to high-quality cash generation and a strong ba
The street is overcomplicating McKesson Corporation (MCK). Per the RQD rating, a 38.6% ROIC combined with Altman Z 6.96 and Piotroski F 7/9 points to high-quality cash generation and a strong balance sheet.. With an RQD score of 85/100 (A-) and Forensic Balance Sheet at 18/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1074.15.
VolSurface_Trader 🐂 BULL
Both sides have a point here — MCK's 18/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH
🎯 Target: $815.56 (-18.0%)
Spot @ $994.58 At P/E (TTM) 24 and EV/EBITDA 19.5, the valuation prices in substantial growth, leaving limited margin for error.
At P/E (TTM) 24 and EV/EBITDA 19.5, the valuation prices in substantial growth, leaving limited margin for error.. Look at the math on MCK: paying 24.0x trailing P/E for 38.6% ROIC and 1.5% operating margins leaves zero margin of safety if Other Pharmaceuticals demand softens. I'd wait for a retest of $875.23 before getting long.